Taro Pharmaceutical Industries Ltd. (TARO) : During the past 4 weeks, traders have been relatively bearish on Taro Pharmaceutical Industries Ltd. (TARO), hence the stock is down -12.08% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -6.3% relative to the S&P 500. The 4-week change in the price of the stock is -12.55% and the stock has fallen -6.15% in the past 1 week.
The stock has recorded a 20-day Moving Average of 7.77% and the 50-Day Moving Average is 15.03%.The 200 Day SMA reached 20.97%
Taro Pharmaceutical Industries Ltd. (NYSE:TARO): The stock opened in the green at $113.78 on Friday, but the bulls found it difficult to push the prices higher. The stock reached a high of $114.2899 and a low of $110.51 for the day. The stock did not find buyers even at the lows and closed at $110.51 recording a loss of -2.54%. 652,741 shares exchanged hands during the trading day. The stock had closed at $110.51 in the previous days trading.
Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company develops, manufactures and markets prescription (Rx) and over-the-counter (OTC) pharmaceutical products, primarily in the United States, Canada and Israel. Taro also develops and manufactures active pharmaceutical ingredients (APIs), primarily for use in its finished dosage form products. The Companys primary areas of focus include semi-solids formulations, such as creams and ointments, and other dosage forms, such as liquids, capsules and tablets, primarily in the dermatological and topical, cardiovascular, neuropsychiatric and anti-inflammatory therapeutic categories. Taros owned product brands include Rokacet, Topicort, Etopan, Lustra and Ovide. Its other generic products include acetazolamide, amiodarone hydrochloride, ammonium lactate, calcipotriene, carbamazepine, cetirizine hydrochloride, ciclopirox olamine, clindamycin, clobetasol propionate and clomipramine hydrochloride.